1. Home
  2. FGII vs TTRX Comparison

FGII vs TTRX Comparison

Compare FGII & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FGII

FG Imperii Acquisition Corp. Class A Ordinary Shares

N/A

Current Price

$9.95

Market Cap

288.0M

Sector

Finance

ML Signal

N/A

Logo Turn Therapeutics Inc.

TTRX

Turn Therapeutics Inc.

HOLD

Current Price

$8.75

Market Cap

281.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FGII
TTRX
Founded
2025
2015
Country
United States
United States
Employees
N/A
2
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
288.0M
281.2M
IPO Year
2026
N/A

Fundamental Metrics

Financial Performance
Metric
FGII
TTRX
Price
$9.95
$8.75
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$8.00
AVG Volume (30 Days)
30.1K
124.9K
Earning Date
N/A
05-31-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.86
$2.57
52 Week High
$9.99
$11.69

Technical Indicators

Market Signals
Indicator
FGII
TTRX
Relative Strength Index (RSI) 55.75 55.17
Support Level N/A $8.51
Resistance Level $9.96 $11.69
Average True Range (ATR) 0.01 1.12
MACD -0.00 -0.10
Stochastic Oscillator 66.67 27.11

Price Performance

Historical Comparison
FGII
TTRX

About FGII FG Imperii Acquisition Corp. Class A Ordinary Shares

FG Imperii Acquisition Corp is a blank check company incorporated in the Cayman Islands. The company was formed for the purpose of merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities.

About TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.

Share on Social Networks: